#	Pagina
attuale pagina	/open-h2020/projects/218054/index.html
-1	/open-h2020/projects/202890/index.html

Opendata, web and dolomites

V.A. Cure SIGNED

A multidisciplinary approach towards sustainable improvement in rare diseases care uniting Europe's top class vascular research to find new treatment strategies for vascular anomalies

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

V.A. Cure project word cloud

Explore the words cloud of the V.A. Cure project. It provides you a very rough idea of what is the project "V.A. Cure" about.

guarantee composition crispr drug editing diseases esrs endothelial laboratories vivo disabilities inducible outside vessel mosaic vas genes uncovering gained initiation microfluidics pharma light identification mechanisms academic writing sequencing multiphoton molecular companies unmet genome sudden positions ipscs outreach causing vitro intersectoral combination treatments generation imaging candidates interaction network industry cure core therapeutic presentation close secondments anomalies rna animal live function seq tissular dissection blood aberrant disease highest establishing display strategies group leveraging 14 treatment assembled plethora academia lacking clinical sheet deletion edge pain rare chronic training trained communication vascular world pathophysiological maintenance models perception confocal technologies phage cas cutting single dysfunction media patients cell death leaders lymph competitive graduates biotech medical

Project "V.A. Cure" data sheet

The following table provides information about the project.

Coordinator	DE DUVE INSTITUTE Organization address address: AVENUE HIPPOCRATE 75 city: BRUXELLES postcode: 1200 website: www.deduveinstitute.be contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Belgium [BE]
Total cost	3˙792˙135 €
EC max contribution	3˙792˙135 € (100%)
Programme	1. H2020-EU.1.3.1. (Fostering new skills by means of excellent initial training of researchers)
Code Call	H2020-MSCA-ITN-2018
Funding Scheme	MSCA-ITN-ETN
Starting year	2019
Duration (year-month-day)	from 2019-03-01 to 2023-02-28

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	DE DUVE INSTITUTE DE DUVE INSTITUTE Organization address address: AVENUE HIPPOCRATE 75 city: BRUXELLES postcode: 1200 website: www.deduveinstitute.be contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	BE (BRUXELLES)	coordinator	512˙640.00
2	ASTRAZENECA AB ASTRAZENECA AB Organization address address: Vastra Maelarhamnen city: SODERTAELJE postcode: 151 85 website: www.astrazeneca.com contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	SE (SODERTAELJE)	participant	563˙965.00
3	UPPSALA UNIVERSITET UPPSALA UNIVERSITET Organization address address: VON KRAEMERS ALLE 4 city: UPPSALA postcode: 751 05 website: www.uu.se contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	SE (UPPSALA)	participant	563˙965.00
4	INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE Organization address address: RUE DE TOLBIAC 101 city: PARIS postcode: 75654 website: www.inserm.fr contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	FR (PARIS)	participant	549˙604.00
5	UNIVERSITAET POTSDAM UNIVERSITAET POTSDAM Organization address address: AM NEUEN PALAIS 10 city: POTSDAM postcode: 14469 website: www.uni-potsdam.de contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DE (POTSDAM)	participant	505˙576.00
6	KAROLINSKA INSTITUTET KAROLINSKA INSTITUTET Organization address address: Nobels Vag 5 city: STOCKHOLM postcode: 17177 website: www.ki.se contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	SE (STOCKHOLM)	participant	281˙982.00
7	OULUN YLIOPISTO OULUN YLIOPISTO Organization address address: PENTTI KAITERAN KATU 1 city: OULU postcode: 90014 website: www.oulu.fi contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	FI (OULU)	participant	280˙805.00
8	SINGH PRATEEK	FI	participant	280˙805.00
9	MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN EV MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN EV Organization address address: HOFGARTENSTRASSE 8 city: MUENCHEN postcode: 80539 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DE (MUENCHEN)	participant	252˙788.00
10	TAMPEREEN YLIOPISTO TAMPEREEN YLIOPISTO Organization address address: Kalevantie 4 city: TAMPERE postcode: 33014 website: www.uta.fi contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	FI (TAMPERE)	participant	0.00
11	BAYER AKTIENGESELLSCHAFT BAYER AKTIENGESELLSCHAFT Organization address address: KAISER-WILHEM-ALLEE 1 city: Leverkusen postcode: 51373 website: http://pharma.bayer.com contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DE (Leverkusen)	partner	0.00
12	BELGIAN VASCULAR ANOMALY PATIENT ASSOCIATION BELGIAN VASCULAR ANOMALY PATIENT ASSOCIATION Organization address address: AVENUE BARON ALBERT D'HUART 192 city: KRAAINEM postcode: 1950 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	BE (KRAAINEM)	partner	0.00
13	CLINIQUES UNIVERSITAIRES SAINT-LUC CLINIQUES UNIVERSITAIRES SAINT-LUC Organization address address: AVENUE HIPPOCRATE 10 city: BRUXELLES postcode: 1200 website: http://www.saintluc.be contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	BE (BRUXELLES)	partner	0.00
14	LLS ROWIAK LASERLABSOLUTIONS GMBH LLS ROWIAK LASERLABSOLUTIONS GMBH Organization address address: GARBSENER LANDSTRASSE 10 city: HANNOVER postcode: 30419 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DE (HANNOVER)	partner	0.00
15	MOLECULINK AB MOLECULINK AB Organization address address: CHEMISTRY BMC - BOX 599 city: UPPSALA postcode: 751 24 website: www.olink.com contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	SE (UPPSALA)	partner	0.00
16	Perimed AB Perimed AB Organization address address: Datavägen 9a city: Järfälla postcode: 17526 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	SE (Järfälla)	partner	0.00
17	Sysmex Inostics GmbH Sysmex Inostics GmbH Organization address address: Falkenried 88 city: Hamburg postcode: 20251 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DE (Hamburg)	partner	0.00
18	TAMPEREEN KORKEAKOULUSAATIO SR TAMPEREEN KORKEAKOULUSAATIO SR Organization address address: KALEVANTIE 4 city: TAMPERE postcode: 33100 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	FI (TAMPERE)	partner	0.00

Map

Project objective

Vascular anomalies (VAs) is a group of rare diseases defined by blood- or lymph vessel dysfunction causing chronic pain, disabilities, and even sudden death, and for which effective treatments are lacking. The European V.A. Cure network aims to address this unmet medical need by uncovering core mechanisms of disease initiation and maintenance and by leveraging this information for establishing novel therapeutic strategies for VAs. V.A. Cure has assembled 7 world-leading academic laboratories and 5 companies, which will apply an intersectoral four-step approach: (1) identification of novel genes involved in VAs in patients, (2) dissection of molecular mechanisms behind the diseases by in vitro modelling, (3) in-depth analysis of tissular mechanisms in pathophysiological conditions through in vivo models, and (4) pre-clinical testing of identified treatment strategies. The knowledge gained will not only be relevant for VAs but also for understanding aberrant vascular function in other vascular-related diseases. The composition of V.A. Cure and close interaction between the 14 ESRs, through secondments in academia and industry, guarantee a unique intersectoral training program at the highest level, ensuring a comprehensive perception of research and drug/technology development in pharma industry/biotech and academia. ESRs will be trained in a plethora of cutting-edge technologies including next-generation sequencing (up to single-cell RNA-Seq), CRISPR-Cas genome editing, generation of animal models with inducible deletion and mosaic analyses, generation of iPSCs, microfluidics, in vivo phage display to identify endothelial targets, and light sheet-, confocal-, and multiphoton live-imaging. In combination with advanced training in management and communication including writing, presentation, e-media and outreach, the graduates of the V.A. Cure network will be future leaders in vascular research, and also highly competitive candidates for positions outside academia.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "V.A. CURE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "V.A. CURE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.1.)

SAMCAPS (2018)

Self-Assembled MicroCAPSules: Synthesis, Characterization, and Eco-friendly Application in Home Care Products

Read More

INSPIRE (2020)

INnovation in Safety Pharmacology for Integrated cardiovascular safety assessment to REduce adverse events and late stage drug attrition.

Read More

WON (2019)

Wideband Optical Networks

Read More